Incepta Pharmaceuticals Ltd. (Incepta)
Incepta Pharmaceuticals Ltd. (Incepta) is one of the leading pharmaceutical companies in Bangladesh. Founded in 1999, it focuses on the research, development, and production of high-quality, innovative medicines. The company offers a wide range of dosage forms, including tablets, capsules, injectables, insulin, biologics, and vaccines, covering multiple therapeutic areas such as oncology, infectious diseases, endocrinology, and cardiovascular health.
Incepta is driven by technological innovation, with expertise in advanced formulations such as sustained-release tablets, orally disintegrating tablets, effervescent tablets, dry powder inhalers, and prefilled syringes. Its modern production facilities comply with international standards, ensuring consistent and reliable product quality. Currently, Incepta exports to more than 100 countries worldwide, gaining strong recognition in global markets.
As Bangladesh’s first manufacturer of human vaccines, Incepta is continually advancing pharmaceutical science, delivering safer, more effective, and affordable treatment solutions for patients worldwide.
At inception, the company was formed by a group of highly skilled, dedicated professionals and led by a capable leadership team. Strategic planning, advanced technology, and fast, effective decision-making have driven its rapid growth. Incepta’s ability to anticipate market demand and deliver the right products at the right time, combined with consistent investment in R&D, has enabled it to stay ahead of competitors with high-quality product launches.
Currently, the Zirabo and Dhamrai plants consist of multiple high-tech buildings, including dedicated facilities for cephalosporin production, lyophilized products, insulin and amino acids, liquid and semi-solid formulations, and large-scale warehouses.
All of Incepta’s products are now manufactured at the Zirabo and Dhamrai plants. The company produces virtually all dosage forms and covers nearly every therapeutic category.
Sales & Distribution
Incepta has one of the largest and strongest sales forces in Bangladesh, supported by a distribution network spanning 28 locations across the country. Its marketing operations are powered by a dynamic, technically proficient, and dedicated team of pharmacists and physicians, who play a key role in strategic product promotion and customer engagement.
Milestones in Incepta’s Development
December 16, 1998
Construction of the Zirabo plant in Savar, Dhaka began.
August 1999
Office operations commenced.
December 1999
First batch of products was manufactured at the Incepta Pharmaceuticals Ltd. facility.
January 2000
Official sales operations began.
February 2000
The first batch of medical representatives underwent training.
April 2000
Incepta launched its first prescription drug, Osartil (Losartan Potassium), marking a new phase of development. Other pioneering products like Celenta (Celecoxib), Rofenta (Rofecoxib), and Omidon (Domperidone) followed.
2003
Continued introduction of innovative and updated drug molecules. A total of 32 new generics were launched, 48 dosage forms—many firsts in Bangladesh. A new sales and distribution office opened in Dhanmondi. Incepta ranked 8th in the country (IMS).
2004
Launched 17 new generics in 32 dosage forms, 6 of which were new to Bangladesh. Ranked 5th nationwide (IMS).
2005
Excelled in new challenges and met growing customer demands. Approved as a supplier by UNICEF and UNDP, and began supplying life-saving medicines to UNICEF from March 2005. A total of 27 new generics were launched in 76 dosage forms, 12 of them new to the country. Ranked 3rd nationwide (IMS).
2016
Incepta Vaccine Ltd. inaugurated its bulk vaccine production facility in Zirabo, Dhaka, on July 28, with the ceremony officiated by Health Minister Mohammad Nasim. That year, Incepta launched three monoclonal antibodies (mAbs) under the brand names:
- Relyto 100 and 500 (Rituximab)
- Denosis 60 and 120 (Denosumab)
- Advixa (Adalimumab)
These were the first locally manufactured monoclonal antibodies in Bangladesh.
In November 2016, the company introduced its first oncology product, Erlotinib 100mg and 150mg, under the brand name Erlocent 100 and 150.
That year, 41 new products were launched, including 11 first-in-Bangladesh innovations.
